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Abstract
Background: Taurine is sulfur containing semi-essential amino acid that has important roles in many biological processes, but; its effects on glucose homeostasis, weight; growth and bone mineralization were not well deﬁned in human.
Objectives: evaluation the effects of oral taurine used for 3 months on bone mineralization biomarker; glycemic control
and body weight in type II diabetic patients.
Methods: interventional double-blind placebo-controlled study in which 80 patients with type2 diabetes mellitus (age
range 45e55) assigned in either control (n ¼ 40) or study (n ¼ 40) group. The last group received 1000 mg capsule of
taurine once a -d for three months. Parameters measured were serum calcium, 25(OH) vitamin D and osteocalcin, NTX-1;
HbA1C% and Fasting blood glucose before and after 3 months.
Results: Taurine led to signiﬁcant (p < 0.05) rise in osteocalcin and signiﬁcant lowering in Body weight and BMI and
there were no signiﬁcant changes in Serum Calcium; NTX-1; Vitamin D; HbA1C% and fasting blood glucose; all as
compared with control values.
Conclusion: 3 months of oral Taurine used in type II diabetic patients may modulate bone mineralization represented
by elevation of osteocalcin; and reduction of body weight, but has no signiﬁcant effect on glycemic control and did not
reduce HbA1C%
Keywords: Taurine, Diabetic patients, Osteocalcin, Body weight, Glycemic control

1. Introduction

D

iabetes Mellitus is a pandemic metabolic
health disturbance featuring chronic hyperglycemia and induce many pathological complications among both sexes in wide range of ages,
these complications include microvascular complications like nephropathy, retinopathy, neuropathy and macrovascular complications like
acute coronary syndrome and stroke [1,2].

In recent years several studies approved that patients with type 2 diabetes mellitus are prone to
osteoporosis and they are at greater risk of developing bone fragility [3]. The main mechanism of
osteoporosis is an imbalance between the activity of
osteoblasts that form bone and osteoclasts that
breakdown bone leading to bone microstructure
deterioration and fractures. [4], other mechanisms
by which diabetes affect bone include hyperglycemia, oxidative stress and accumulation of advanced
glycation end products (AGEs) [5].
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Uncontrolled blood glucose level in type-2 diabetic patients can affect bone metabolism and its
fragility directly or in directly leading to the change
in the level of bone biochemical markers in blood or
urine. The most sensitive markers include osteocalcin (OC), the bone formation marker measured in
serum, other biomarkers can be recommended is Nterminal telopeptide (NTX) as a reference marker
for bone resorption [6,7]. The antidiabetic medications have variable effects on bone metabolism; may
be positive or negative impact. Metformin, the most
known biguanide, has positive effect on osteogenesis via activation of osteoblast-speciﬁc Runx2
(run-related transcription factor2) and activation of
AMP-activated protein kinase [8,9]. At the same
time has negative effect on differentiation of osteoclast [10]. Taurine is semi-essential or conditional
amino acid, present in large amount in human and
animal tissues [11], but its endogenous production is
insufﬁcient, therefore it must be provided by diet
[12], or given as supplement. Taurine exhibit antioxidant and anti-inﬂammatory actions as well as has
many beneﬁcial roles in diabetes because it is able
to block toxicity caused by oxidative stress [13], it
also has role in osmoregulation, in counteracting
inﬂammation and glucose homeostasis [14]. The
novelty of this study is that Effects of taurine 100 mg
orally for glycemic control, bone mineralization and
body weight have not measured in human patients
before.
1.1. Aims of study
Evaluation effect of oral taurine used for 3months
on bone mineralization biomarker; glycemic control
and body weight in type II diabetic patient.

2. Subjects and methods
2.1. Study design
Randomized double-blind placebo-controlled
study; The study was carried out from October 2017
to December 2018 in Al Basra General Hospital.
Basra city e southern of Iraq. After agreement of
scientiﬁc and ethical committees in college of
pharmacy and hospital.
2.2. Patients selection
2.2.1. Inclusion criteria
Adult patient; with age range 45e55 years old,
diagnosed with diabetes Mellitus type 2; and each
patient used medical diabetes treatment no more
than ﬁve years.

2.2.2. Exclusion criteria
Diseases include malignancy, thyroid problems;
parathyroid; pregnancy or breastfeeding, medications' use; like vitamin D; calcium supplements; ant
obesity medications or blends; steroids, bisphosphonates and insulin at least one mo before starting
study and for the next 3 months of study. Changes
in any medication for diabetes control.
2.3. Sample size determination
Was determined using G power® V3.1 software
assuming 1:1 subject division (control: study) the
response within each subject group was normally
distributed with standard deviation 5. If the true
difference in the study and control means is 5, we
will need, at least; to study 40 subjects for study and
40 control subjects to be able to reject the null hypothesis that the means of the study and control
groups are equal with probability (power) 0.82. The
Type I error probability associated with this test of
this null hypothesis is 0.05.
2.4. Study groups
Each Diabetic patient that fulﬁlled the requirement of study is asked to sign a written consent and
then be randomly allocated; by the use of simple
randomization, into either control or study group.
Only 80 patients completed the study successfully.
Control group (n ¼ 40, age 50.2 ± 3.7 years; 24
males & 16 females) received placebo treatment
once daily and.
Study group (n ¼ 40, age 48.8 ± 3.1 years; 22 males
& 18 females) received Taurine 1000 mg capsule
(Jarrow's formulas) orally once daily. There was no
signiﬁcant difference in average ages and male: female ratio between groups.
Hospital's pharmacist informed Each patient
informed about the goals of the study and full the
taurine. Each patient included in the study after
signing of a written consent.
Height of the patient was registered at the
beginning of study in addition to Body weight, body
mass index was measured for each patient before
and after 3months.
2.5. Sampling
A venous blood sample was drawn from each
participant, for measuring fasting blood glucose;
HbA1C%; serum calcium; Osteocalcin; Serum NTX
(N- terminal telopeptide); 25-(OH)Vitamin D level;
before and three months after administration their
assigned supplement.
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2.6. Data analysis
Data analyzed using MedCalc® software V12. The
data was expressed as mean ± Standard deviation.
One-way anova was used to ﬁnd the signiﬁcant
(p < 0.05) effects between the groups.
Independent sample t-test was used for comparison
between groups and paired t-test was used to ﬁnd the
signiﬁcant of difference between pre-and after treatment values within each group. P value < 0.05 was
considered as signiﬁcant (see Table 1).

3. Results
3.1. Demographic data of patients
As in Table 2 There were no signiﬁcant (p < 0.05)
differences between control and study group. In age
(50.2 ± 3.7 Vs. 48.8 ± 3.1; p value ¼ 0.072); male:
female ratio (24:16 for control Vs. 22:18 for study; p
value ¼ 0.821); weight (kgs) (98 ± 14.5 Vs. 95.8 ± 13.3;
p value ¼ 0.324); Height (cm) (172.6 ± 7.5 Vs.
171 ± 6.2; p value ¼ 0.326), Body mass index

(33.1 ± 5.8 Vs. 32.9 ± 5.1; p value ¼ 0.821); obesity
ratio (75% control Vs. 70% study. p value ¼ 0.802);
fasting Blood glucose (121.5 ± 9.8 for control Vs.
122.6 ± 12.2 for study group; p value ¼ 0.544), Glycosylated hemoglobin (HbA1C%) (7.3 ± 0.6 for
control Vs. 7.5 ± 0.6 for study group; p value ¼ 0.168)
and diabetes duration in years (2.7 ± 1.7 for control
Vs. 3.1 ± 1.6 for study group; p value ¼ 0.342).
3.2. Bone mineralization bio markers
Osteocalcin raised signiﬁcantly (p < 0.05) in study
group after using taurine for 3months as compared
with its baseline value (28.9 ± 10.7 after treatment vs.
17.7 ± 12.3 for baseline); and also, it was signiﬁcantly
(p < 0.05) higher than values of control group
(28.9 ± 10.7 after treatment for study group vs.
18.3 ± 5.9 for control). As in Table 3.
Serum Vitamin D elevated signiﬁcantly (p < 0.05)
in study group after using taurine for 3 months as
compared with its baseline value (20.8 ± 6.8 after
treatment vs. 18.8 ± 6.7 for baseline); this elevation

Table 1. Shows name and source of kits used to measure the parameters of study.
Parameters

Kit

Source

Fasting blood glucose
Serum calcium
Osteocalcin
NTX-1 (N terminal telopeptidase of
type1 collagen)
Serum 25-OH-Vitamin D

Glucose Assay Kit (Colorimetric)
Calcium Assay Kit
Osteocalcin (1e43/49) ELISA
Human Cross linked N terminal Telopeptides of
type I collagen ELISA Kit
25-OH-Vitamin D direct ELISA

Cell Biolab, INC
BD biosciences, USA
ALPCO diagnostics
MyBioSource, US
IBL INTERNATIONAL GMBH

Table 2. Demographic data of patients in the study groups. Some of data expressed as Mean ± standard deviation.
Age (years)
Male: female ratio
Weight (kg)
Height (cm)
Body mass index (kg/m2)
Obesity ratio
Fasting Blood glucose (mg/dl)
HbA1c%
Diabetes duration (years)

Control group N ¼ 40

Study group N ¼ 40

P values

50.2 ± 3.7
24:16
98 ± 14.5
172.6 ± 7.5
33.1 ± 5.8
30 (75%)
121.5 ± 9.8
7.3 ± 0.6
2.7 ± 1.7

48.8 ± 3.1
22:18
95.8 ± 13.3
171 ± 6.2
32.9 ± 5.1
28 (70%)
122.6 ± 12.2
7.5 ± 0.6
3.1 ± 1.6

0.072
0.821
0.324
0.326
0.821
0.802
0.544
0.168
0.342

P values < 0.05 considered as signiﬁcant values.
Table 3. Comparison of bone mineralization biomarkers in both study groups; before and after treatment. Values are expressed as Mean ± standard
deviation.

Osteocalcin (ng/ml)
Serum Vit. D (ng/ml)
Serum Calcium (mg/dl)
NTX-1 (ng/ml)

Control group N ¼ 40

Study group N ¼ 40

Baseline

After treatment

Baseline

After treatment

17.4 ± 5.6
19 ± 5.3
7.1 ± 2
20.4 ± 7.1

18.3 ± 5.9
20.3 ± 5.4*
7.3 ± 1.9
20 ± 6.8

17.7 ± 12.3
18.8 ± 6.7
7.1 ± 2.1
20 ± 8.9

28.9 ± 10.7*a
20.8 ± 6.8*
7.6 ± 2.5*
18.3 ± 7.6

P values < 0.05 considered as signiﬁcant values.
*signiﬁcant (p < 0.05) as compared to its baseline values.
a
signiﬁcant (p < 0.05) as compared to control value.

P values

0.00002
0.378
0.695
0.605
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was not signiﬁcant (p < 0.05) as compared to control
value (20.8 ± 6.8 for study vs. 20.3 ± 5.4 for control).
As in Table 3.
Serum calcium elevated signiﬁcantly (p < 0.05) in
study group after using taurine for 3 months as
compared with its baseline value (7.6 ± 2.5 after
treatment vs. 7.1 ± 2.1 for baseline); this elevation
was not signiﬁcant (p < 0.05) as compared to control
value (7.6 ± 2.5 for study vs. 7.3 ± 1.9 for control). As
in Table 3.
N- terminal telopeptide (NTX-1) was not signiﬁcantly (p < 0.05) changed in both groups even after
treatment. As in Table 3.
3.3. Glycemic control markers
Fasting Blood glucose was not signiﬁcantly
(p < 0.05) changed in both groups even after treatment. As in Table 3.
Glycosylated hemoglobin (HbA1C%) was not
signiﬁcantly (p < 0.05) changed in both groups even
after treatment. As in Table 4.
3.4. Effect on body weight
Percent change in Both body weight lowered
signiﬁcantly (p < 0.05) in study group after using
taurine for 3 months as compared with control
values (2.5 ± 4.3 for study vs. 0.43 ± 5.8 for control).
And same for body mass index was (2.4 ± 4.3for
study vs. 0.41 ± 5.8for control). As in Table 5.

4. Discussion
Taurine contains sulfur amino acid that available
in mammalian tissues. A lot of studies talked about
its functions and its roles in many known biological
processes, e.g., calcium metabolism, protein phosphorylation, energy extraction and etc. Despite the
importance of taurine in these biological functions,
its interaction in the regulation of glucose

homeostasis, weight; growth and bone metabolism
remain not well deﬁned [15].
In this study; taurine supplement used for 3
months in type 2 diabetic patients and used to study
its effect on biochemical markers related to bones
mineralization; diabetes control and effect on body
weight.
Taurine administration as supplement was able to
raise the serum level of osteocalcin signiﬁcantly
(p < 0.05); as in Table 3. This ﬁnding was different
from results of many studies that found the use of
Taurine have not result in signiﬁcant change in the
level of osteocalcin [16e19].
Taurine stimulates osteoblast resulted in secreting
osteocalcin [20,21]. Due to oral supplementation;
taurine probably was available in blood in sufﬁcient
concentration to produce sustain raise in osteocalcin
level in the blood of taurine treated group [20,21]
that reﬂected as signiﬁcant rising as compared to
control group.
Taurine may enhance intestinal absorption of fatsoluble vitamins; like vitamin D [22] and studies
found low taurine dietary intake may compromise
vitamin D absorption [23]. In this study; taurine
supplement did signiﬁcantly enhance intestinal absorption of vitamin D; so that serum level of 25
(hydroxy)Vitamin D was elevated signiﬁcantly in
group used taurine. But unfortunately; these
changes were not signiﬁcant as compared to control
group.
Serum calcium changes in this study was parallel
to changes in vitamin D level.
In addition to that; Blood N- terminal telopeptide;
a bone resorption biomarker; that secreted by the
activity of osteoclasts [24] was not signiﬁcantly
changed by taurine supplement. This may indicate
that Taurine may not stimulate osteoclast probably
not enhance bone turnover activities.
Serum calcium was not also changed signiﬁcantly
as compared to control group.

Table 4. Comparison of changes in percentage of glycemic control parameters in both study groups. Values are expressed as Mean ± standard
deviation.
% change Fasting Blood Glucose
% HbA1c

Control group N ¼ 40

Study group N ¼ 40

P values

0.4 ± 15.2
1.1 ± 7.4

0.2 ± 2.2
1.5 ± 10.7

0.934
0.211

P values < 0.05 considered as signiﬁcant values.

Table 5. Comparison of percentage changes in Body weight & BMI for both study groups. Values are expressed as Mean ± standard deviation.
% change in Weight (kg)
% change in BMI

Control group N ¼ 40

Study group N ¼ 40

P values

0.43 ± 5.8
0.41 ± 5.8

2.5 ± 4.3
2.4 ± 4.1

0.014
0.015

P values < 0.05 considered as signiﬁcant values.
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Taurine may suppress insulin secretion in nondiabetic pancreatic islets, and may serve as a regulator
factor for insulin secretion and blood glucose level.
[25]; enhancer for peripheral insulin sensitivity
[26],and taurine may have hypoglycemic effect [27].
There were no signiﬁcant changes in the level of
fasting blood glucose or HbA1C% measures during
the study this in agreement with M. Zhang et al., 2004
that found no signiﬁcant change in Fasting blood
glucose after 7 weeks from using taurine supplement
in non-diabetic individuals [28]. Although so Body
weight and BMI index was signiﬁcantly reduced after
treatment with taurine but this was not signiﬁcant as
compared to control group. This ﬁnding was in
agreement to M. Zhang et al., 2004 [28].

5. Conclusion

[2]
[3]

[4]
[5]
[6]
[7]
[8]

[9]

Taurine 1000 mg orally use in type II diabetic
patients may modulate bone mineralization represented by elevation of osteocalcin; and may reduce
body weight but has no signiﬁcant effect on glycemic control and did not reduce HbA1C%
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